Results 211 to 220 of about 148,501 (250)
Some of the next articles are maybe not open access.
Current Treatment Options in Neurology, 2000
More than a century after its initial clinicopathologic description, amyotrophic lateral sclerosis (ALS) remains a largely fatal, progressive neurodegenerative disorder for which few efficacious pharmacotherapies with an impact directly on the natural course of the illness exist. The only currently approved therapy, the antiglutamatergic agent riluzole,
, Demaerschalk, , Strong
openaire +2 more sources
More than a century after its initial clinicopathologic description, amyotrophic lateral sclerosis (ALS) remains a largely fatal, progressive neurodegenerative disorder for which few efficacious pharmacotherapies with an impact directly on the natural course of the illness exist. The only currently approved therapy, the antiglutamatergic agent riluzole,
, Demaerschalk, , Strong
openaire +2 more sources
Seminars in Neurology, 1998
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with evidence of both anterior horn cell and corticospinal tract degeneration. The incidence of ALS is 1 to 2.5 cases per 100,000 population and the disease occurs primarily in adult life. The etiology of sporadic ALS remains unknown, although 5 to 10% of cases are familial. The diagnosis of
C E, Jackson, W W, Bryan
openaire +2 more sources
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with evidence of both anterior horn cell and corticospinal tract degeneration. The incidence of ALS is 1 to 2.5 cases per 100,000 population and the disease occurs primarily in adult life. The etiology of sporadic ALS remains unknown, although 5 to 10% of cases are familial. The diagnosis of
C E, Jackson, W W, Bryan
openaire +2 more sources
2019
Amyotrophic lateral sclerosis (ALS) is caused by selective and progressive loss of spinal, bulbar and cortical motoneurons and leads to irreversible paralysis, loss of speech, inability to swallow and respiratory malfunctions with the eventual death of the affected individual in a rapid disease course.
Klara, Valko, Lukasz, Ciesla
openaire +2 more sources
Amyotrophic lateral sclerosis (ALS) is caused by selective and progressive loss of spinal, bulbar and cortical motoneurons and leads to irreversible paralysis, loss of speech, inability to swallow and respiratory malfunctions with the eventual death of the affected individual in a rapid disease course.
Klara, Valko, Lukasz, Ciesla
openaire +2 more sources
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Medicinal research reviews (Print), 2018Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but failed to show efficacy in human clinical trials or are still waiting for ...
M. Jaiswal
semanticscholar +1 more source
Amyotrophic lateral sclerosis: translating genetic discoveries into therapies.
Nature reviews genetics, 2023F. Akçimen +6 more
semanticscholar +1 more source
Amyotrophic lateral sclerosis in pregnancy
International Journal of Gynecology & Obstetrics, 1993Amyotrophic lateral sclerosis is rare in the obstetric population; only one case has been described in the last 18 years. Two pregnant women with this disease were observed within a 1-year period in Minneapolis.A twin pregnancy was diagnosed in a woman during hospital admission for evaluation of a pure lower motor neuron degenerative process.
A.S. Hanson +3 more
openaire +3 more sources
Effect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis
Annals of Neurology, 2019Weight loss has been identified as a negative prognostic factor in amyotrophic lateral sclerosis, but there is no evidence regarding whether a high‐caloric diet increases survival.
A. Ludolph +20 more
semanticscholar +1 more source
Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis
Journal of Neurology Neurosurgery & Psychiatry, 2018Objective To determine the diagnostic and prognostic performance of serum neurofilament light chain (NFL) in amyotrophic lateral sclerosis (ALS). Methods This single-centre, prospective, longitudinal study included the following patients: 124 patients ...
F. Verde +17 more
semanticscholar +1 more source
Behaviour in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis, 2008We wished to determine whether patients with amyotrophic lateral sclerosis (ALS) show behavioural changes similar to those of frontotemporal dementia (FTD). There is accumulating evidence to suggest a link between ALS and FTD, yet there has been little systematic exploration of behaviour in ALS. An informant based semi-structured behavioural interview,
Gibbons, Zoe C. +3 more
openaire +3 more sources
Neuroimaging in amyotrophic lateral sclerosis
European Journal of Neurology, 1999Amyotrophic lateral sclerosis (ALS) is a chronic degenerative disorder of unknown etiology affecting the motor system. Conventional and non‐conventional neuroimaging techniques can provide essential help both to increase the confidence in ALS diagnosis and to assess the disease evolution.
COMI , GIANCARLO +2 more
openaire +7 more sources